The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Analysts at William Blair lifted their Q2 2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. William Blair analyst L.

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Empaveli (pegcetacoplan) for two rare and severe ...

Less than two weeks after having its funding temporarily cut by the state, the Fairhope Public Library is getting recognized ...

Nobody likes sweaty feet. Not on ourselves, not on our partners, not on anyone close to us, in physical distance and in ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.